Auro Laboratories Ltd
Auro Laboratories Ltd (AUROLAB) last traded at ₹235, a market capitalisation of ₹146 crore, on a P/E of 66.6. Over the past 52 weeks the stock has ranged between ₹159 and ₹317. Auro Laboratories Ltd last reported results for the quarter ended Sep 2025, with sales of ₹8.84 crore and net profit of ₹0.72 crore. Figures are as of 25 Aug 2026 and are not real time.
Auro Laboratories Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Auro Laboratories Ltd quarterly results
| ₹ crore | Sep 2024 | Jun 2025 | Sep 2025 |
|---|---|---|---|
| Sales | 3.1 | 2.77 | 8.84 |
| Expenses | 2.38 | 2.74 | 6.49 |
| Operating profit | 0.72 | 0.03 | 2.35 |
| OPM % | 23.23% | 1.08% | 26.58% |
| Other income | 0.31 | 0.42 | 0.98 |
| Interest | 0.28 | 0.28 | 0.96 |
| Depreciation | 0.27 | 0.27 | 0.65 |
| Profit before tax | 0.48 | -0.1 | 1.72 |
| Tax % | 25.00% | 0.00% | 58.14% |
| Net profit | 0.36 | -0.11 | 0.72 |
| EPS (₹) | 0.58 | -0.18 | 1.16 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Auro Laboratories Ltd annual results
| ₹ crore | Mar 2025 |
|---|---|
| Sales | 19.4 |
| Operating profit | 3.4 |
| OPM % | 17.53% |
| Net profit | 1.84 |
| EPS (₹) | 2.95 |
TTM is the trailing twelve months to the most recent quarter.
Auro Laboratories Ltd growth and returns
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- TTM
- %
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- TTM
- %
- 10 Years
- 22%
- 5 Years
- 13%
- 3 Years
- 29%
- 1 Year
- -4%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- Last Year
- 4%
Auro Laboratories Ltd shareholding pattern
Promoters held 52.40% at Jun 2026, broadly unchanged since Jun 2025. DIIs 0.01%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 52.15% | 52.15% | 52.17% | 52.17% | 52.17% | 52.17% | 52.17% | 52.40% |
| DIIs | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% |
| Public | 47.84% | 47.84% | 47.82% | 47.82% | 47.82% | 47.80% | 47.82% | 47.58% |
| No. of shareholders | 9,266 | 9,265 | 9,102 | 8,916 | 8,860 | 8,640 | 8,405 | 8,315 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Auro Laboratories Ltd corporate filings
- Auro Laboratories Limited has submitted the clippings of newspaper publications of the Un-audited Financial Results for the quarter ended June 30, 2026.Company Updatehigh impact
Cruxal's analysis: Auro Laboratories Limited reported a robust performance for the quarter ended June 30…
Read the full analysis - Auro Laboratories Limited has submitted the Outcome of the Board Meeting held on August 14, 2026Board Meetinghigh impact
Cruxal's analysis: Auro Laboratories Limited has reported a significant financial turnaround for the quarter…
Read the full analysis - Auro Laboratories Limited has submitted the Scrutinizer Report of 37th AGM held on August 11, 2026.AGM/EGMlow impact
Cruxal's analysis: Auro Laboratories Limited has successfully concluded its 37th Annual General Meeting held…
Read the full analysis - Auro Laboratories Limited has submitted the Proceedings/Outcome of the 37th Annual General Meeting held on August 11, 2026.AGM/EGMlow impact
Cruxal's analysis: Auro Laboratories Limited has successfully concluded its 37th Annual General Meeting held…
Read the full analysis - Auro Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve Unaudited Financial Results ....Board Meetinglow impact
Cruxal's analysis: Auro Laboratories Limited has issued a formal intimation regarding a Board of Directors…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Auro Laboratories Ltd
Cruxal reads every Auro Laboratories Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.